Pasithea Therapeutics Corp. (NASDAQ:KTTA) Financings

Pasithea Therapeutics Corp.

Financings

RaiseDate
Public offering of common stock (or pre-funded warrants in lieu thereof)
Closed: US$60M raised · US$0.75 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Vivo Capital; Janus Henderson Investors; Coastlands Capital; Columbia Threadneedle Investments; Adage Capital Partners; Squadron Capital Management
Use of proceeds: General corporate purposes, including research, clinical trials and working capital
Dec 2, 2025
Public offering of common stock (or pre-funded warrants) with Series C and Series D warrants
Closed: US$5M raised · US$1.4 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, licensing, acquisitions and working capital
May 7, 2025
Warrant exercise of series D warrants
Closed: US$1.3M raised · US$1.4 a share
May 7, 2025

Read by 6ix AI from the company's releases